Nicoya Therapeutics
Privately held: no public share price · China
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Extended-release calcifediol(Rayaldee) | Approved | Vitamin D receptor (VDR), via conversion to calcitriolSmall molecule | Chronic Kidney Disease Secondary Hyperparathyroidism |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
October 2027 (1)
Extended-release calcifediol · RayaldeePhase 2CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
Est. primary completion 2027-10 · NCT07494045 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.